IPP Bureau

Quality Care India partners Intuitive to take robotic surgery beyond metros
Quality Care India partners Intuitive to take robotic surgery beyond metros

By IPP Bureau - March 25, 2026

Nova IVF Fertility expands in Kerala with acquisition of Craft Fertility
Nova IVF Fertility expands in Kerala with acquisition of Craft Fertility

By IPP Bureau - March 25, 2026

The timing of the partnership is crucial, as Kerala’s fertility rate has dropped to approximately 1.35–1.7 children per woman, below the replacement level of 2.1

Novartis strikes $3 billion deal to acquire next-gen breast cancer drug
Novartis strikes $3 billion deal to acquire next-gen breast cancer drug

By IPP Bureau - March 25, 2026

SNV4818, the oral drug, is pan-mutant–selective PI3K? inhibitor aimed at treating HR+/HER2- breast cancer and potentially other solid tumors

Earendil Labs bags $787m to supercharge AI-driven biologics pipeline
Earendil Labs bags $787m to supercharge AI-driven biologics pipeline

By IPP Bureau - March 25, 2026

Capital infusion to accelerate Earendil’s R&D platform

ImmunityBio scores first Asian approval for ANKTIVA in Macau
ImmunityBio scores first Asian approval for ANKTIVA in Macau

By IPP Bureau - March 25, 2026

The Macau authorization followed a regulatory review that considered prior decisions by both the US FDA) and the European Medicines Agency

Siemens Healthineers expands radiotherapy beyond cancer, targets osteoarthritis pain
Siemens Healthineers expands radiotherapy beyond cancer, targets osteoarthritis pain

By IPP Bureau - March 25, 2026

The radiotherapy systems include TrueBeam, TrueBeam STx, VitalBeam, and Edge

Roche inaugurates new research home for the Institute of Human Biology
Roche inaugurates new research home for the Institute of Human Biology

By IPP Bureau - March 24, 2026

The Institute of Human Biology (IHB) enables scientists to pioneer human model systems, accelerating the development of new medicines to improve the lives of patients

Japan okays new long-acting eye drug
Japan okays new long-acting eye drug

By IPP Bureau - March 24, 2026

It promises fewer injections for vision loss patients

Bayer wins world-first nod in Japan for low-dose MRI contrast agent
Bayer wins world-first nod in Japan for low-dose MRI contrast agent

By IPP Bureau - March 24, 2026

Call it a major breakthrough for diagnostic imaging

Pfizer and Valneva report promising Phase 3 Lyme disease vaccine results
Pfizer and Valneva report promising Phase 3 Lyme disease vaccine results

By IPP Bureau - March 24, 2026

The company plans to submit the vaccine for regulatory review

Bristol Myers Squibb unveils new Camzyos data, expands case for landmark heart drug
Bristol Myers Squibb unveils new Camzyos data, expands case for landmark heart drug

By IPP Bureau - March 24, 2026

The company’s ACC lineup underscores a growing body of evidence backing the drug’s performance beyond controlled trials

Somerset smashes fund target, raises $288M to power India’s healthcare transformation
Somerset smashes fund target, raises $288M to power India’s healthcare transformation

By IPP Bureau - March 24, 2026

Zydus launches affordable Semaglutide in India after patent expiry
Zydus launches affordable Semaglutide in India after patent expiry

By IPP Bureau - March 23, 2026

Targets diabetes & obesity crisis as India grapples with soaring metabolic disorders

Glenmark slashes cost barrier with India launch of GLIPIQ diabetes therapy
Glenmark slashes cost barrier with India launch of GLIPIQ diabetes therapy

By IPP Bureau - March 23, 2026

The once-weekly treatment targets Type 2 Diabetes Mellitus (T2DM) with demonstrated efficacy and safety

Godavari Biorefineries secures Japanese patent for antiviral compounds
Godavari Biorefineries secures Japanese patent for antiviral compounds

By IPP Bureau - March 23, 2026

The patent protects antiviral compounds developed by the company that inhibit Vacuolar ATPase (V-ATPase) activity in cells, a mechanism involved in viral infection pathways

Latest Stories

Interviews

Packaging